Physician profile
Emily Brown
NPI 1598347601
$4,006.59
in general payments reported to CMS, 2019-2025
22 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $128 · 2023: $962 · 2024: $1,367 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,703 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,702.95 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $649.01 | 2023-2025 | |
| Alkermes, INC. | $498.59 | 2022-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $472.08 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $310.68 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $291.80 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $247.78 | 2023-2025 | Ingrezza |
| Corium, LLC | $229.81 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $224.49 | 2023-2024 | Spravato |
| Vanda Pharmaceuticals INC. | $223.36 | 2024-2025 | Fanapt |
| Indivior INC. | $153.58 | 2023-2024 | Perseris |
| Almatica Pharma LLC | $133.29 | 2024-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $91.29 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $89.70 | 2024-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $80.88 | 2024-2025 | Rexulti |
| Noven Therapeutics, LLC | $57.50 | 2024 | Xelstrym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $54.65 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $42.18 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $39.31 | 2025 | Cobenfy |
| Tempus Ai, INC | $38.02 | 2024 | |
| Luye Pharma (USA) LTD. | $32.47 | 2025 | Erzofri Extended-Release |
| Takeda Pharmaceuticals U.S.A., INC. | $30.79 | 2024 | Trintellix |
| Owp Pharmaceuticals, INC. | $15.33 | 2023 | Lamotrigine, Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.